<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144622</url>
  </required_header>
  <id_info>
    <org_study_id>201412135MINC</org_study_id>
    <nct_id>NCT03144622</nct_id>
  </id_info>
  <brief_title>18F-FSPG PET/CT Imaging in Patients With Cancers</brief_title>
  <official_title>(4S)-4-(3-[18F]Fluoropropyl)-L-glutamate Radiotracer (FSPG) PET/CT for Imaging xC- Transporter Activity in Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the diagnostic performance of 18F-FDG and 18F-FSPG PET/CT in lung,
      breast, and abdominal cancers before undergoing therapy. In addition, the role of 18F-FSPG
      PET/CT in evaluating therapy response and prognosis will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Staging ability of 18F-FSPG PET/CT</measure>
    <time_frame>3 years</time_frame>
    <description>Sensitivity, specificity, diagnostic accuracy of 18F-FSPG and 18F-FDG PET/CT will be compared according to patient-based and lesion-based analysis using paired t-test or Krusal-Wallis test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ability of 18F-FSPG PET/CT in therapy response evaluation and prognosis prediction</measure>
    <time_frame>3 years</time_frame>
    <description>Comparison between 18F-FSPG and 18F-FDG PET/CT will be done using both qualitative and quantitative measures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uptake of 18F-FSPG</measure>
    <time_frame>3 years</time_frame>
    <description>Standardised uptake values (SUV) will be compared between 18F-FSPG and 18F-FDG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of 18F-FSPG PET/CT</measure>
    <time_frame>3 years</time_frame>
    <description>Number of reported adverse events</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pulmonary Cancer</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Abdominal Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with clinical diagnosis of NSCLC, breast, and abdominal cancers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients are given the opportunity to participate in the study if

               1. Age â‰¥ 20 years old.

               2. Confirmed diagnosis of primary cancer of the following: NSCLC, breast or
                  abdominal cancers

               3. ECOG performance status 0 to 2.

               4. Life expectancy &gt; 3 months.

               5. Consent to perform additional 18F-FSPG and 18F-FDG PET prior to therapy.

               6. Sexually active subjects agree to use condoms and/or their partners of
                  reproductive potential to use a method of effective birth control during imaging
                  period of 2 weeks.

        Exclusion Criteria:

          -  Patients with any of the following conditions will be excluded

               1. Had received previous treatment (excluding neoadjuvant therapy).

               2. Pregnant or lactating women.

               3. Known malignancy in other organs.

               4. Evaluated by primary care physician as unsuitable.

               5. Known hypersensitivity to the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mei-Fang Cheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital Department of Nuclear Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mei-Fang Cheng, MD</last_name>
    <phone>886-02-23123456</phone>
    <phone_ext>65901</phone_ext>
    <email>meifang@ntuh.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei-Fang Cheng, MD</last_name>
      <phone>886-02-23123456</phone>
      <phone_ext>65901</phone_ext>
      <email>meifang@ntuh.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>(4S)-4-(3-[18F]fluoropropyl-)-L-glutamate</keyword>
  <keyword>18F-FSPG</keyword>
  <keyword>PET/CT</keyword>
  <keyword>system xC-transporter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

